fruquintinib
Drug Details
- Generic Name
- fruquintinib
- Brand Names
- Fruzaqla
- Application Number
- NDA217564
- Sponsor
- Takeda Pharmaceuticals America, Inc.
- NDC Codes
- 2
- Dosage Forms
- CAPSULE
- Routes
- ORAL
- Active Ingredients
- FRUQUINTINIB
Indications and Usage
1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. ( 1 )